Minsheng Securities released a research report on April 26 stating that it gave Ganli Pharmaceutical (603087.SH) a recommended rating. The main reasons for the rating include: 1) rapid growth in product sales, which turned a loss into a profit in 2023; 2) collection accelerated domestic replacement, and the company achieved rapid release of products; 3) renewals accelerated the pace of replacing second-generation insulin, further expanding the company's procurement base; 4) increasing investment in R&D and continuing to strengthen the sugar reduction product line; 5) speeding up the pace of going global and steadily advancing internationalization. (Mainichi Keizai Shimbun)
民生证券4月26日发布研报称，给予甘李药业（603087.SH）推荐评级。评级理由主要包括：1）产品销量迅速增长，2023年实现扭亏为盈；2）集采加速国产替代，公司产品实现快速放量；3）续约加速三代替换二代胰岛素步伐，公司获得采购基础量进一步扩大；4）加强研发投入，降糖产品线持续发力；5）加快走出去步伐，稳步推进国际化进展。（每日经济新闻）
Minsheng Securities released a research report on April 26 stating that it gave Ganli Pharmaceutical (603087.SH) a recommended rating. The main reasons for the rating include: 1) rapid growth in product sales, which turned a loss into a profit in 2023; 2)
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.